StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies on Compass Pathways (CMPS): 'We are 75-85%+ confident FDA approves COMP360 for TRD depression'
September 9, 2026 10:46 AM
Jefferies analyst Andrew Tsai reiterated a Buy rating and $18.00 price target on Compass Pathways (NASDAQ: CMPS).The analyst comments "Big ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
